X

Trial Profile

Phase II Clinical Trial of Dasatinib Therapy Aiming for Treatment-Free Remission in Patients with Chronic Phase Chronic Myeloid Leukemia

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 11 May 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasatinib (Primary)
Indications Chronic myeloid leukaemia
Focus Therapeutic Use
Acronyms D-Free

Most Recent Events

01 May 2023 Results assessing Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia published in the International Journal of Hematology
14 Dec 2021 Status changed to discontinued.
14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com